Retraction: Multidrug-resistance related long non-coding RNA expression profile analysis of gastric cancer (PLoS ONE( 2015) 10:8: (e0135461) DOI:10.1371/journal.pone.0135461);Multidrug-resistance related long non-coding RNA expression profile analysis of gastric cancer

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Wang, Ying ^a,b   Wu, Kaichun ^a   Yang, Zhiping ^a   Zhao, Qingchuan ^a   Fan, Dongmei ^b   Xu, Po ^b   Nie, Yongzhan ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; STEROID REDUCTASE; TRANSCRIPTOME;

ARTICLE; CANCER CELL; CARD15 GENE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DNA POLYMORPHISM; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE; NOD1 GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION; VALIDITY; BIOLOGY; DRUG RESISTANCE; GENETICS; PROCEDURES; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; RNA, LONG NONCODING; STOMACH NEOPLASMS; TRANSCRIPTOME; UP-REGULATION;

EID: 84942942462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0226210     Document Type: Erratum

References (56)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATPCdependent transporters. Nature Reviews Cancer. 2002; 2(1):48-58. PMID: 11902585
2. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. miR©(c)15b and miR© (c)16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer. 2008; 123 (2):372-9.
3. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009; 136 (4):629-41. doi:10.1016/j.cell.2009.02.006 PMID: 19239885
4. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non© (c)coding RNAs: regulators of disease. The Journal of pathology. 2010; 220(2):126-39. doi: 10.1002/path.2638 PMID: 19882673
5. Willingham A, Orth A, Batalov S, Peters E, Wen B, Aza-Blanc P, et al. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science. 2005; 309(5740):1570. PMID: 16141075
6. Sunwoo H, Dinger ME, Wilusz JE, Amaral PP, Mattick JS, Spector DL. MEN ε/β nuclear-retained noncoding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome research. 2009; 19(3):347. doi:10.1101/gr.087775.108 PMID: 19106332
7. Sone M, Hayashi T, Tarui H, Agata K, Takeichi M, Nakagawa S. The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear domain in a subset of neurons. Journal of cell science. 2007; 120 (15):2498-506.
8. Mattick JS. The genetic signatures of noncoding RNAs. PLoS Genet. 2009; 5(4):e1000459. doi: 10.1371/journal.pgen.1000459 PMID: 19390609
9. Pibouin L, Villaudy J, Ferbus D, Muleris M, Prospéri MT, Remvikos Y, et al. Cloning of the mRNA of overexpression in colon carcinoma-1:: a sequence overexpressed in a subset of colon carcinomas. Cancer genetics and cytogenetics. 2002; 133(1):55-60.PMID: 11890990
10. Guffanti A, Iacono M, Pelucchi P, Kim N, Sold G, Croft LJ, et al. A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC genomics. 2009; 10(1):163.
11. Krawczyk M, Emerson BM. p50-associated COX-2 extragenic RNA (PACER) activates COX-2 gene expression by occluding repressive NF-κB complexes. eLife. 2014; 3.
12. Szafranski P, Dharmadhikari AV, Wambach JA, Towe CT, White FV, Grady RM, et al. Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins. American Journal of Medical Genetics Part A. 2014.
13. Wu Z-H, Wang X-L, Tang H-M, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncology Reports.
14. Liu J-H, Chen G2, Dang Y-W, Li C-J, Luo D-Z. Expression and Prognostic Significance of lncRNA MALAT1 in Pancreatic Cancer Tissues. Asian Pacific journal of cancer prevention: APJCP. 2014; 15 (7):2971. PMID: 24815433
15. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014; 5(8):2318-29. PMID: 24810858
16. Hu M-L, Yeh K-T, Lin P-M, Hsu C-M, Hsiao H-H, Liu Y-C, et al. Deregulated expression of circadian clock genes in gastric cancer. BMC gastroenterology. 2014; 14(1):67.
17. Yang MY, Chang JG, Lin PM, Tang KP, Chen YH, Lin HYH, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer science. 2006; 97(12):1298-307. PMID: 16999817
18. Hsu C-M, Lin S-F, Lu C-T, Lin P-M, Yang M-Y. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumor Biology. 2012; 33(1):149-55. doi:10.1007/s13277-011-0258-2 PMID: 22081375
19. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Molecular carcinogenesis. 2008; 47(12):925-33. doi:10.1002/mc.20446 PMID: 18444243
20. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology. 2003; 21(20):3808-13. PMID: 14551299
21. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology. 2005; 16(2):254-8. PMID: 15703542
22. Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach W, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cellular microbiology. 2006; 8(7):1188-98. PMID: 16819970
23. Özen SC, Daʇli Ü, Kiliç MY, Törüner M, Çelik Y, Özkan M, et al. NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease. Journal of gastroenterology. 2006; 41(4):304-10. PMID: 16741608
24. Lener MR, Oszutowska D, Castaneda J, Kurzawski G, Suchy J, Nej-Wolosiak K, et al. Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast cancer research and treatment. 2006; 95(2):141-5. PMID: 16267612
25. Liu J, He C, Xu Q, Xing C, Yuan Y. NOD2 Polymorphisms Associated with Cancer Risk: A Meta-Analysis. PloS one. 2014; 9(2):e89340. doi: 10.1371/journal.pone.0089340 PMID: 24586700
26. Walters TD, Silverberg MS, Lal S, Lim S, Griffiths AM. Contribution of Dlg5, Mdr1, Nod1/Card4 and Tlr4 to Pediatric Onset Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition. 2006; 43(4):E71.
27. Slotwinski R, Dabrowska A, Lech G, Slodkowski M. Innate immunity in pancreatic cancer patients and changes after immuno-enhancing nutrition (P1308). The Journal of Immunology. 2013; 190:63.11.
28. Grange J, Bottasso O, Stanford J. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine. 2008; 26(39):4984-90. doi: 10.1016/j.vaccine.2008.06.092 PMID:18625281
29. Zhang H, Chin AI. Role of Rip2 in Development of Tumor-Infiltrating MDSCs and Bladder Cancer Metastasis. PloS one. 2014; 9(4):e94793. doi: 10.1371/journal.pone.0094793 PMID: 24733360
30. Tuere-Oezdemir F, Gazouli M, Tzivras M, Panagos C, Bovaretos N, Petraki K, et al. Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer research. 2008; 28(6A):3697-700. PMID: 19189651
31. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. Journal of Clinical Oncology. 2007; 25(27):4262-9. PMID: 17724347
32. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert opinion on therapeutic targets. 2013; 17(9):1073-80. doi: 10.1517/14728222.2013.819853 PMID: 23865553
33. Wang Y, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding rna mrul promotes abcb1 expression in multidrug-resistant gastric cancer cell sublines. Molecular and cellular biology. 2014; 34(17):3182-93. doi: 10.1128/MCB.01580-13 PMID: 24958102
34. Li T, Wang H, Sun Y, Zhao L, Gang Y, Guo X, et al. Transcription factor CUTL1 is a negative regulator of drug resistance in gastric cancer. Journal of Biological Chemistry. 2013; 288(6):4135-47. doi: 10.1074/jbc.M112.345942 PMID: 23255599
35. Xue Z, Yan H, Li J, Liang S, Cai X, Chen X, et al. Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. Journal of cellular biochemistry. 2012; 113(1):302-12. doi: 10.1002/jcb.23356 PMID: 21913215
36. Wang L, Yin F, Du Y, Chen B, Liang S, Zhang Y, et al. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin. Tumor Biology. 2010; 31(3):225-32. doi: 10.1007/s13277-010-0036-6 PMID: 20440596
37. Liu L, Zhang H, Sun L, Gao Y, Jin H, Liang S, et al. ERK/MAPK activation involves hypoxia-induced MGr1-Ag/37LRP expression and contributes to apoptosis resistance in gastric cancer. International Journal of Cancer. 2010; 127(4):820-9.
38. Wang Y, Gao S, Liu G, Jia R, Fan D, Feng X. Microarray Expression Profile Analysis of Long Non-Coding RNAs in Human Gastric Cardiac Adenocarcinoma. Cellular Physiology and Biochemistry. 2014; 33 (4):1225-38. doi: 10.1159/000358692 PMID: 24751403
39. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, et al. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014; 5(6):1434. PMID: 24727738
40. Arase M, Horiguchi K, Ehata S, Morikawa M, Tsutsumi S, Aburatani H, et al. Transforming growth factor-β-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC (A) cells. Cancer science. 2014.
41. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, et al. The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer. Molecular Cancer Research. 2014.
42. Li W, Kang Y. A New Lnc in Metastasis: Long Noncoding RNA Mediates the ProMetastatic Functions of TGF-β. Cancer cell. 2014; 25(5):557-9. doi: 10.1016/j.ccr.2014.04.014 PMID: 24823634
43. Shieh J-M, Shen C-J, Chang W-C, Cheng H-C, Chan Y-Y, Huang W-C, et al. An Increase in Reactive Oxygen Species by Deregulation of ARNT Enhances Chemotherapeutic Drug-Induced Cancer Cell Death. 2014.
44. Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L, et al. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget. 2015; 6(8):6431-47. PMID: 25669983
45. Gu C, Gonzalez J, Zhang T, Kamel-Reid S, Wells RA. The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells. Leukemia research. 2013; 37(12):1750-6. doi: 10.1016/j.leukres.2013.10.010 PMID: 24220583
46. Wu H, Hait WN, Yang J-M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer research. 2003; 63(7):1515-9. PMID: 12670898
47. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Current pharmaceutical design. 2006; 12(3):273-86. PMID: 16454744
48. Ren F, Wang D-B, Li T, Chen Y-H, Li Y. Identification of differentially methylated genes in the malignant transformation of ovarian endometriosis. Journal of ovarian research. 2014; 7(1):73.
49. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature genetics. 2014; 46(4):376-9. doi:10.1038/ng.2921 PMID:24633157
50. Sun B, Yang N, Jiang Y, Zhang H, Hou C, Ji C, et al. Antagomir-1290 suppresses CD133+ cells in nonsmall cell lung cancer by targeting fyn-related Src family tyrosine kinase. Tumor Biology. 2015:1-8. PMID: 25783528
51. Zhao Y, You H, Liu F, An H, Shi Y, Yu Q, et al. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer letters. 2002; 185(2):211-8. PMID: 12169395
52. Wang Y, Feng X, Jia R, Liu G, Zhang M, Fan D, et al. Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma. Molecular Genetics and Genomics. 2014; 289(3):291-302. doi: 10.1007/s00438-013-0810-4 PMID: 24414129
53. Lee S-W, Kim Y-M, Kim M-B, Kim D-Y, Kim J-H, Nam J-H, et al. In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer. Acta medica Okayama. 2012; 66 (3):271-7. PMID: 22729108
54. Gwak H-S, Park HJ, Yoo H, Youn SM, Rhee CH, Lee SH. Chemotherapy for Malignant Gliomas Based on Histoculture Drug Response Assay: A Pilot Study. Journal of Korean Neurosurgical Society. 2011; 50(5):426-33. doi: 10.3340/jkns.2011.50.5.426 PMID: 22259689
55. Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods. 2004; 33 (2):95-103. PMID: 15121163
56. Johnson SC. Hierarchical clustering schemes. Psychometrika. 1967; 32(3):241-54. PMID: 5234703